Bristol Myers Squibb Company $BMY Holdings Lowered by S Bank Fund Management Ltd

Key Points

• S Bank Fund Management Ltd has drastically reduced its holdings in Bristol Myers Squibb by 77.6%, selling 83,435 shares and leaving them with only 24,061 shares, valued at approximately $1.1 million.
• Despite S Bank's sell-off, other institutional investors like WealthPlan Investment Management and Callahan Advisors have increased their stakes in Bristol Myers Squibb during the same quarter.
• The company recently announced a quarterly dividend of $0.62 per share, representing a yield of 5.7%, with a payout ratio of 100% and scheduled for payment on November 3rd.

S Bank Fund Management Ltd reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 77.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,061 shares of the biopharmaceutical company's stock after selling 83,435 shares during the period. S Bank Fund Management Ltd's holdings in Bristol Myers Squibb were worth $1,114,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. WealthPlan Investment Management LLC lifted its stake in Bristol Myers Squibb by 61.0% in the 2nd quarter. WealthPlan Investment Management LLC now owns 11,002 shares of the biopharmaceutical company's stock worth $509,000 after acquiring an additional 4,167 shares in the last quarter. Callahan Advisors LLC lifted its stake in Bristol Myers Squibb by 36.9% in the 2nd quarter. Callahan Advisors LLC now owns 11,491 shares of the biopharmaceutical company's stock worth $532,000 after acquiring an additional 3,095 shares in the last quarter. New York State Teachers Retirement System lifted its stake in Bristol Myers Squibb by 3.4% in the 2nd quarter. New York State Teachers Retirement System now owns 1,821,758 shares of the biopharmaceutical company's stock worth $84,329,000 after acquiring an additional 59,294 shares in the last quarter. Rosenberg Matthew Hamilton lifted its stake in Bristol Myers Squibb by 130.8% in the 2nd quarter. Rosenberg Matthew Hamilton now owns 3,799 shares of the biopharmaceutical company's stock worth $176,000 after acquiring an additional 2,153 shares in the last quarter. Finally, Mutual Advisors LLC lifted its stake in Bristol Myers Squibb by 29.2% in the 2nd quarter. Mutual Advisors LLC now owns 88,992 shares of the biopharmaceutical company's stock worth $4,310,000 after acquiring an additional 20,095 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.09% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Daiwa America downgraded Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Dbs Bank raised Bristol Myers Squibb to a "moderate buy" rating in a research report on Thursday, October 2nd. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Bristol Myers Squibb in a research report on Tuesday. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Finally, Citigroup reissued a "neutral" rating on shares of Bristol Myers Squibb in a report on Monday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fifteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of "Hold" and a consensus price target of $57.14.

Bristol Myers Squibb Stock Performance

BMY opened at $43.63 on Thursday. The firm has a market capitalization of $88.81 billion, a P/E ratio of 17.59, a price-to-earnings-growth ratio of 2.26 and a beta of 0.33. The stock's 50 day moving average price is $46.16 and its two-hundred day moving average price is $47.79. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The firm had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company's revenue was up .6% on a year-over-year basis. During the same quarter last year, the firm posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.7%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.